For All Your Latest Medical News, Health News, COVID-19 News, H5N1 News, Long COVID News And News About The Thailand Medical Industry

Source: Vaccine News  Jan 27, 2021  2 years ago
Vaccine News: Immunologists Warns US FDA On The Immunological Danger Of COVID-19 Vaccination In Recently Convalescent And Asymptomatic Carriers!
Vaccine News: Immunologists Warns US FDA On The Immunological Danger Of COVID-19 Vaccination In Recently Convalescent And Asymptomatic Carriers!
Source: Vaccine News  Jan 27, 2021  2 years ago
Vaccine News: Media outlets are abuzz in the last 24 hours about a warning letter sent to the US FDA and Pfizer by a leading immunologist cum scientist in Pennslyvania, Dr  Hooman Noorchashm.

The letter warns about the immunological danger of COVID-19 Vaccination in recently convalescent and asymptomatic carriers most especially to those who are elderly, frail or have significant cardiovascular risk factors.
The physician stressed, “I want to be clear that my warning is based on a near definitive scientific Immunological prognostication. It is a ‘prognostication’ in that I have put it forth in the absence of clear evidence of it being a material risk. This is because we are dealing with an evolving 11-month old national health emergency with many unknowns, and a vaccine that is only several weeks old. And, in a setting where it is critical to quickly vaccinate as many citizens as possible to achieve herd immunity.”
Dr Noorcahshm also stressed that he is an ardent supporter of President Biden’s plan to vaccinate 150 Million Americans in 100 days and that it is not his intention that his warnings be abused by political, uninformed or conspiratorial forces attempting to dissuade the American public about the near certain importance of being vaccinated to achieve herd immunity and protect the country.
Dr Noorcahshm says that the SARS-CoV-2 virus has tropism for the vascular endothelium, among other tissues and organs. This fact was captured in a study published in the Lancet in 2020.
It appears that the ACE-2 receptor on endothelium is the portal for viral entry into endothelial cells and it seems that endothelial injury from the virus or from the inflammatory reaction it incites, is the reason why many COVID-19 patients experience thromboembolic complications.
Hence it is a matter of certainty that viral antigens are present in the endothelial lining of blood vessels in all persons with active or recent infection-irrespective of whether they are symptomatic or convalescent.

Dr Noorcahshm warns that it is an almost certain immunological prognotication that if viral antigens are present in the tissues of subjects who undergo vaccination, the antigen specific immune response triggered by the vaccine will target those tissues and cause tissue inflammation and damage.
Importantly, when viral antigens are present in the vascular endothelium, and especially in elderly and frail vasculopath, the antigen specific immune response incited by the vaccine is almost certain to do damage to the vascular endothelium.
It must be noted that such vaccine directed endotheliitis is certain to cause blood clot formation with the potential for major thromboembolic complications, at least in a subset of such patients. If a majority of younger more robust patients might tolerate such vascular injury, many elderly, frail vasculopaths will not.
Dr Noorcahshm  is requesting that the U.S. FDA, in coll aboration with Pfizer and Moderna, immediately and at the very minimum, institute a clear recommendation to clinicians to delay immunization in any recently convalescent patients, as well as, any known asymptomatic carriers and to actively screen any patients who are at high cardiovascular risk for the presence of SARS-CoV-2 antigen.
Also potential reasonable solution, especially in the nursing home setting, would be to use antibody screening as a surrogate means of excluding/delaying vaccination in persons who might have been exposed to the SARS-CoV-2 coronavirus and have viral antigens lingering in their tissues.
He stresses that the goal of maximally and quickly vaccinating the population as quickly as possible is the correct public health goal. It will save many lives and certainly far more lives than any vaccine related complication might compromise.
However, in the present national emergency, simply because we know that the majority of citizens in our society will benefit from vaccination cannot justify a failure to mitigate against known and rationally prognosticated risks to a minority subset.
He said that as an immunologist with a good understanding of how antigen specific immune responses could cause organ and tissue specific damage, I he is recommending lead FDA regulators to not to gloss over the real possibility that vaccinating persons with pre-existing SARS-CoV-2 viral antigens in their tissues could cause that subset of people grave harm and especially in the frail with cardiovascular risk.
Also if the immunological risk he is prognosticating herein is reality material, over the next months as millions more Americans are being immunized, it will become quite visible to the public.
He warns of a possible scenario where the public, without having received any warning from U.S.FDA, becomes aware of such a complication if it materializes. There would be widespread “vaccine hesitancy” and a demand of accountability by the public of U.S experts and federal regulators especially if they knew or should have known that this immunologically possibility existed.
He said that the aim of benefiting the majority of the public and saving the nation from this pandemic by quick and aggressive vaccination is an ethically sound one “but where we know of real or likely risks of harm, we ought to mitigate those in potential harms way. So doing is the only reasonable (and likely constitutional) option you can pursue as public health regulators  for in America, we no longer sacrifice the lives of minority subsets of people for the benefit of the majority.”
It should be noted that thromboembolic complications, 10–20 days following activation of a vaccine induced antigen specific immune response, in elderly frail vasculopaths, will not register as “vaccine related complications”….but SARS-CoV-2 is a virus with tropism for the vascular endothelium….and the Pfizer and Moderna vaccines could easily direct an antigen specific immune attack to that very target organ.
As of the last few hours, Pzifer, Moderna or the US.FDA has yet to respond to the immunologist warnings.
Please help share this article to as many so that more doctors and physicians and also individuals are made aware of this possible risk and necessary protocols are adhered.
For the latest Vaccine News, keep on Logging to Thailand Medical News.


Sep 25, 2022  8 months ago
Source: Medical News - SARS-CoV-2 Fall And Winter 2022 Variant Collections
Sep 08, 2022  9 months ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 04, 2022  10 months ago
Source: Medical News - SARS-CoV-2 & Cancer
Aug 13, 2020  3 years ago
Source: Supplements For COVID-19
Feb 05, 2020  3 years ago
Source : Thailand Medical news